301 filings
Page 5 of 16
8-K
errcukt8iorp7
14 Jan 21
Oragenics Issues Letter to Stockholders
7:14am
8-K
zs4k1s 6oe5p646p5
7 Jan 21
Oragenics Enters into Material Transfer Agreement with Adjuvance Technologies for COVID-19 Vaccine Adjuvant
7:22am
8-K
f33x28l7
29 Dec 20
Oragenics Announces Closing of $6.5 Million Registered Direct Offering
4:17pm
8-K
i3ibfk
28 Dec 20
Oragenics, Inc. Announces $6.5 Million Registered Direct Offering
5:04pm
8-K
22t23
24 Nov 20
Oragenics Announces Closing of $6.0 Million Underwritten Public Offering
11:59am
8-K
9sx3g7qkfppdm0ok0
20 Nov 20
Oragenics Prices $5.25 Million Common Stock Offering
8:44am
8-K
cvz27u
19 Nov 20
Oragenics Announces Proposed Underwritten Public Offering
5:18pm
8-K
cixr3s83u iu1w
10 Nov 20
Regulation FD Disclosure
4:35pm
8-K
n3tgh1hx6biqpa1iv5x
6 Oct 20
FDA Broadly Supports Oragenics’ Pre-IND Development Program for its SARS-CoV-2 Vaccine
7:48am
8-K
ylp9lae
28 Sep 20
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
7:45am
8-K
i62y 5gr5w3gz0
11 Sep 20
Oragenics Inc. to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
8:53am
8-K
b2wgs5k9cvmnyddzm
24 Aug 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
a65wy36nvk
20 Aug 20
Other Events
8:54am
8-K
0if7bfzp rigunciez
18 Aug 20
Regulation FD Disclosure
7:55am
8-K/A
1djd7
14 Aug 20
Financial Statements and Exhibits
4:22pm
8-K
2nlzcui7ung8y5g3z
27 Jul 20
Other Events
7:49am
8-K
yl6v3pm8c42bp6btqks9
22 Jul 20
Regulation FD Disclosure
7:58am
8-K
bs8r b2by2
10 Jul 20
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
7:49am
8-K
8esn 90yi1a023nld
5 Jun 20
Entry into a Material Definitive Agreement
4:00pm
8-K/A
x0xvac4t5 sw6oa
29 May 20
Audited Financial Statements
4:05pm